( August 22, 2025, 1:19 PM EDT) -- NEW ORLEANS — Upholding a Texas federal judge’s “wayward view” in granting summary judgment to the U.S. Food and Drug Administration and Eli Lilly and Co. in a dispute over whether the agency properly determined that the shortage of tirzepatide, a drug for diabetes and weight loss, would “end judicial review of agency action as it has existed for generations,” companies representing the interests of drug compounders tell the Fifth Circuit U.S. Court of Appeals in an opening brief made public on Aug. 21....